161 related articles for article (PubMed ID: 3099881)
1. Superficial bladder cancer: intravesical chemotherapy and tumour progression to muscle invasion or metastases.
Smith G; Elton RA; Chisholm GD; Newsam JE; Hargreave TB
Br J Urol; 1986 Dec; 58(6):659-63. PubMed ID: 3099881
[TBL] [Abstract][Full Text] [Related]
2. Intravesical chemotherapy for superficial bladder cancer.
Koontz WW
Urology; 1984 Apr; 23(4 Suppl):79-81. PubMed ID: 6424298
[No Abstract] [Full Text] [Related]
3. Severe bladder contracture in patient receiving intravesical mitomycin C for superficial bladder cancer.
Baker WC; Russo MA; deVere White RW
Urology; 1987 Oct; 30(4):357-8. PubMed ID: 3116739
[TBL] [Abstract][Full Text] [Related]
4. Transitional cell carcinoma of the prostate following intravesical therapy for transitional cell carcinoma of the bladder.
Hardeman SW; Perry A; Soloway MS
J Urol; 1988 Aug; 140(2):289-92. PubMed ID: 3135420
[TBL] [Abstract][Full Text] [Related]
5. Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times.
Giesbers AA; Van Helsdingen PJ; Kramer AE
Br J Urol; 1989 Feb; 63(2):176-9. PubMed ID: 2495144
[TBL] [Abstract][Full Text] [Related]
6. Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma.
Kalsi J; Harland SJ; Feneley MR
Expert Opin Drug Deliv; 2008 Jan; 5(1):137-45. PubMed ID: 18095933
[TBL] [Abstract][Full Text] [Related]
7. Use of intravesical cisplatin and mitomycin-C for recurrent transitional cell carcinoma of bladder refractory to thiotepa.
Mobley WC; Loening SA; Narayana AS; Culp DA
Urology; 1986 Apr; 27(4):335-9. PubMed ID: 3083555
[TBL] [Abstract][Full Text] [Related]
8. The significance of tumour grade in predicting disease progression in stage Ta transitional cell carcinoma of the urinary bladder.
Chen SS; Chen KK; Lin AT; Chang YH; Wu HH; Hsu TH; Chang LS
Br J Urol; 1996 Aug; 78(2):209-12. PubMed ID: 8813915
[TBL] [Abstract][Full Text] [Related]
9. Treatment schedule of intravesical chemotherapy with mitomycin C in superficial bladder cancer: short-term courses or maintenance therapy.
van der Meijden AP; DeBruyne FM
Urology; 1988 Mar; 31(3 Suppl):26-9. PubMed ID: 3126592
[TBL] [Abstract][Full Text] [Related]
10. Intravesical chemotherapy: studies on the relationship between osmolality and cytotoxicity.
Groos E; Masters JR
J Urol; 1986 Aug; 136(2):399-402. PubMed ID: 3090275
[TBL] [Abstract][Full Text] [Related]
11. Bladder wall calcification after intravesical mitomycin C treatment of superficial bladder cancer.
Drago PC; Badalament RA; Lucas J; Drago JR
J Urol; 1989 Oct; 142(4):1071-2. PubMed ID: 2507794
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of intravesical Epodyl therapy for superficial bladder cancer.
Mufti GR; Virdi JS; Hall MH
Br J Urol; 1990 Jan; 65(1):32-5. PubMed ID: 2310930
[TBL] [Abstract][Full Text] [Related]
13. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
[TBL] [Abstract][Full Text] [Related]
14. Conservative treatment of high grade superficial bladder tumours.
Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of intravesical mitomycin C in the treatment of superficial transitional cell carcinoma of the urinary bladder.
Pavlotsky A; Eidelman A; Barak F; Alon H; Horn Y
J Surg Oncol; 1989 May; 41(1):9-11. PubMed ID: 2497274
[TBL] [Abstract][Full Text] [Related]
16. Intravesical chemotherapy. Studies on the relationship between pH and cytotoxicity.
Groos E; Walker L; Masters JR
Cancer; 1986 Sep; 58(6):1199-203. PubMed ID: 3091241
[TBL] [Abstract][Full Text] [Related]
17. The ultrastructure of transitional cell carcinomas of the human urinary bladder treated with ethoglucid or mitomycin.
Stewart RJ; Lawson AH; Weaver JP
J Urol; 1988 Jun; 139(6):1355-8. PubMed ID: 3373614
[TBL] [Abstract][Full Text] [Related]
18. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
Soloway MS; Jordan AM; Murphy WM
Prog Clin Biol Res; 1989; 310():215-36. PubMed ID: 2505268
[TBL] [Abstract][Full Text] [Related]
19. Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study.
Heney NM; Koontz WW; Barton B; Soloway M; Trump DL; Hazra T; Weinstein RS
J Urol; 1988 Dec; 140(6):1390-3. PubMed ID: 3143016
[TBL] [Abstract][Full Text] [Related]
20. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
